A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
ಸುದ್ದಿಯ ಸಾರಾಂಶ
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
ವಿಶ್ವಾಸಾರ್ಹ ಪ್ರಕಾಶಕರ ಇತ್ತೀಚಿನ ಸುದ್ದಿಗಳನ್ನು ಸಂಕ್ಷಿಪ್ತ ಸಾರಾಂಶಗಳೊಂದಿಗೆ ಓದಿ. ವಿವರಗಳಿಗೆ ಮೂಲ ಲಿಂಕ್ ತೆರೆಯಿರಿ.